Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. (August 2008)
- Record Type:
- Journal Article
- Title:
- Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. (August 2008)
- Main Title:
- Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes
- Authors:
- Srivastava, Vibhuti
Deshpande, Smita N
Nimgaonkar, Vishwajit L
Lerer, Bernard
Thelma, BK - Abstract:
- Aim: Olanzapine is an efficacious drug often used as a first-line medication in the treatment for schizophrenia. However, weight gain is a notable adverse drug reaction of this medication in a proportion of patients and a major cause of noncompliance. Several hypotheses, including a contribution from hormonal, physiological and environmental factors, have been postulated. In this study, we aimed to analyze a possible association of genetic polymorphisms at four important candidate genes involved in appetite regulation and antipsychotic-induced metabolic syndrome with olanzapine-induced weight gain.Materials & methods: A total of 154 schizophrenia subjects were recruited in a systematic, 6-week, open-label trial of olanzapine. We investigated the contribution of 14 polymorphisms from four genes, namely, leptin, lipoprotein lipase, tri-acyl-glycerol lipase and citrate lyase using a binary logistic regression analysis towards olanzapine-induced weight gain.Results: rs 4731426 C/G SNP, a variant in the leptin gene, was moderately associated with median weight gain (ΔΔ weightm ; [p = 0.05; OR: 2.2; 95% CI: 0.99––4.90]) and significantly associated with extreme weight gain (ΔΔ weighte [p = 0.019; OR: 11.43; 95% CI: 1.49––87.55]) when average drug dose was included in a regression model. Using in silico analysis, we found that this associated intronic SNP in the leptin gene alters the binding of zinc finger 5, a transcription factor.Conclusion: The leptin gene may be aAim: Olanzapine is an efficacious drug often used as a first-line medication in the treatment for schizophrenia. However, weight gain is a notable adverse drug reaction of this medication in a proportion of patients and a major cause of noncompliance. Several hypotheses, including a contribution from hormonal, physiological and environmental factors, have been postulated. In this study, we aimed to analyze a possible association of genetic polymorphisms at four important candidate genes involved in appetite regulation and antipsychotic-induced metabolic syndrome with olanzapine-induced weight gain.Materials & methods: A total of 154 schizophrenia subjects were recruited in a systematic, 6-week, open-label trial of olanzapine. We investigated the contribution of 14 polymorphisms from four genes, namely, leptin, lipoprotein lipase, tri-acyl-glycerol lipase and citrate lyase using a binary logistic regression analysis towards olanzapine-induced weight gain.Results: rs 4731426 C/G SNP, a variant in the leptin gene, was moderately associated with median weight gain (ΔΔ weightm ; [p = 0.05; OR: 2.2; 95% CI: 0.99––4.90]) and significantly associated with extreme weight gain (ΔΔ weighte [p = 0.019; OR: 11.43; 95% CI: 1.49––87.55]) when average drug dose was included in a regression model. Using in silico analysis, we found that this associated intronic SNP in the leptin gene alters the binding of zinc finger 5, a transcription factor.Conclusion: The leptin gene may be a promising candidate for olanzapine-induced weight gain. As the associations are modest, replicate studies are warranted. This approach may facilitate rationalized drug regimens. … (more)
- Is Part Of:
- Pharmacogenomics. Volume 9:Number 8(2008)
- Journal:
- Pharmacogenomics
- Issue:
- Volume 9:Number 8(2008)
- Issue Display:
- Volume 9, Issue 8 (2008)
- Year:
- 2008
- Volume:
- 9
- Issue:
- 8
- Issue Sort Value:
- 2008-0009-0008-0000
- Page Start:
- 1055
- Page End:
- 1068
- Publication Date:
- 2008-08
- Subjects:
- adverse drug reaction -- leptin -- north India -- obesity -- olanzapine -- schizophrenia
Pharmacogenomics -- Periodicals
615.1 - Journal URLs:
- http://www.futuremedicine.com/loi/pgs ↗
http://www.futuremedicine.com/ ↗ - DOI:
- 10.2217/14622416.9.8.1055 ↗
- Languages:
- English
- ISSNs:
- 1462-2416
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.249500
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 16461.xml